Literature DB >> 19523351

Antiepileptic drugs and other medications: what interactions may arise?

Ram Mani1, John R Pollard.   

Abstract

Many patients with epilepsy are on lifelong therapy with antiepileptic drugs (AEDs), and AEDs are used for other conditions such as mood stabilization and headache prophylaxis. These drugs have high potential for clinically significant interaction with nonepilepsy drugs. Interactions occur largely through altered pharmacokinetics. One drug may increase the hepatic clearance of another, leading to attenuated efficacy of the affected drug. Alternatively, inhibition of liver metabolism by one drug can cause acute toxicity by reducing clearance of another drug. To identify potential drug interactions before they lead to toxicity or therapy failure, the treating clinician should combine knowledge of the patient's overall history with a general knowledge of comorbid conditions in which significant interactions involving AEDs are most likely to occur. Treatments susceptible to interactions include anticoagulants, antiarrhythmics, antibiotics, antiretroviral drugs, immunosuppressives, antineoplastics, and contraceptives. Therefore, it is important to obtain periodically a thorough history of medical problems, use of medications or herbal remedies, and adverse effects of medications. Physicians managing epilepsy patients should also strive to avoid potential drug interactions by favoring low-interaction AEDs in patients taking many other types of drugs. There is quite a large degree of patient heterogeneity in the extent of any given interaction between an AED and another drug. Indeed, some groups of patients may have different susceptibilities to such interactions because of genetic and environmental influences on drug metabolism. Effective treatment with AEDs should include attention to drug interactions.

Entities:  

Year:  2009        PMID: 19523351     DOI: 10.1007/s11940-009-0029-1

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  31 in total

Review 1.  Antiepileptic drug interactions.

Authors:  J A French; B E Gidal
Journal:  Epilepsia       Date:  2000       Impact factor: 5.864

Review 2.  Cytochrome P450 and therapeutic drug monitoring with respect to clozapine.

Authors:  B Buur-Rasmussen; K Brøsen
Journal:  Eur Neuropsychopharmacol       Date:  1999-12       Impact factor: 4.600

Review 3.  Optimizing therapy of seizures in patients with brain tumors.

Authors:  Charles J Vecht; Melanie van Breemen
Journal:  Neurology       Date:  2006-12-26       Impact factor: 9.910

Review 4.  Optimizing therapy of seizures in patients with renal or hepatic dysfunction.

Authors:  Glenda Lacerda; Thierry Krummel; Cécile Sabourdy; Philippe Ryvlin; Edouard Hirsch
Journal:  Neurology       Date:  2006-12-26       Impact factor: 9.910

5.  Antiepileptic drugs: coprescription of proconvulsant drugs and oral contraceptives: a national study of antiepileptic drug prescribing practice.

Authors:  S D Shorvon; R C Tallis; H K Wallace
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-01       Impact factor: 10.154

Review 6.  Clinically relevant drug interactions with antiepileptic drugs.

Authors:  Emilio Perucca
Journal:  Br J Clin Pharmacol       Date:  2006-03       Impact factor: 4.335

7.  Oxcarbazepine does not affect the anticoagulant activity of warfarin.

Authors:  G Krämer; B Tettenborn; P Klosterskov Jensen; G P Menge; K D Stoll
Journal:  Epilepsia       Date:  1992 Nov-Dec       Impact factor: 5.864

Review 8.  Seizures in HIV-seropositive individuals: NIMHANS experience and review.

Authors:  P Satishchandra; Sanjib Sinha
Journal:  Epilepsia       Date:  2008-08       Impact factor: 5.864

Review 9.  Interaction between valproic acid and carbapenem antibiotics.

Authors:  Hitomi Mori; Kazuhiko Takahashi; Takaharu Mizutani
Journal:  Drug Metab Rev       Date:  2007       Impact factor: 4.518

10.  Influence of rifampicin and isoniazid on the kinetics of phenytoin.

Authors:  L Kay; J P Kampmann; T L Svendsen; B Vergman; J E Hansen; L Skovsted; M Kristensen
Journal:  Br J Clin Pharmacol       Date:  1985-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.